Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the latest addition to guideline-directed medical therapy in heart failure (HF) with reduced ejection fraction with recent trials suggesting a significant reduction in adverse cardiovascular ...

2019年10月12日 · Results from current CVOTs show promise for SGLT‐2 inhibitors in the prevention of HF in patients with T2D across a spectrum of cardiovascular risk.

Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have dramatic beneficial cardiovascular outcomes. These include a reduced incidence of cardiovascular death and heart failure hospitalization in people with and without diabetes, and those with and without prevalent heart failure.

2025年3月26日 · SGLT2 Inhibitors in Heart Failure: New Evidence Changes Treatment Protocols Quick video summary of the detailed article below. Introduction Heart failureis a global health challenge, affecting over 64 million people worldwide. It is a major cause of hospital stays and deaths. The five-year survival rate is just 25% for patients with reduced ejection fraction who …

2022年9月3日 · SGLT2 inhibitors reduced the risk of cardiovascular death and hospitalisations for heart failure in a broad range of patients with heart failure, supporting their role as a foundational therapy for heart failure, irrespective of ejection fraction or care setting.

Key Considerations For Use of SGLT2i in Patients With Heart Failure. May contribute to volume depletion. Consider altering diuretic dose if applicable. *Stage A: At Risk for HF but without symptoms, structural heart disease, or cardiac biomarkers of stretch or injury.

SGLT2 inhibitors (SGLT2i) are new drugs for patients with heart failure (HF) irrespective of diabetes. However, the mechanisms of SGLT2i in HF remain elusive. This article discusses the current clinical evidence for using SGLT2i in different types ...

2025年3月29日 · DapaTAVI trial showed dapagliflozin reduced all-cause death or worsening heart failure by 28% in TAVR patients. SGLT2 inhibitors, including dapagliflozin, are safe and beneficial for elderly patients with heart failure undergoing TAVR. Adverse events were high in both study arms, but dapagliflozin did not increase urinary tract infections.

2024年5月17日 · Sodium–glucose co-transporter-2 (SGLT2) inhibitors have been studied in patients with heart failure, type 2 diabetes, chronic kidney disease, atherosclerotic cardiovascular disease, and acute myocardial infarction. Individual trials were powered to study composite outcomes in one disease state.

2025年3月3日 · Sodium-glucose cotransporter-2 inhibitors (SGLT2i), initially developed as antihyperglycemic agents, have revolutionized heart failure (HF) management, offering substantial benefits across all stages and phenotypes of the disease. Regardless of left ventricular ejection fraction (LVEF), these agents …